Jacobio to Start US/China Trials of KRAS Inhibitor in Solid Tumor Cancers

Beijing 's Jacobio Pharma announced US approval to start trials of its KRAS G12C inhibitor in patients with advanced solid tumors. The company plans to enroll patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors that have the KRAS G12C mutation. So far, no KRAS G12C inhibitors have been approved globally. China approved a similar IND application in March. Jacobio will start enrolling patients for both trials in the second half of 2021. More details.... Stock Symbol: (HK: 1167) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.